Abstract: A reading device includes a base on which a read target object is placed, a reader that reads the read target object placed on the base, a first attachment frame to which the reader is attached such that the reader is disposed above the base, an operation unit that is used for operating the reading device by touching, a second attachment frame to which the operation unit is attached such that the operation unit is disposed above the base, and a support frame that has a first surface and a second surface more bendable than the first surface in response to an external force. The first attachment frame is fixed to the first surface of the support frame. The second attachment frame is fixed to the second surface of the support frame.

Abstract: A caster protection structure protects a caster provided at a base of a housing and used for transporting the housing in a movable manner, and includes a frame member that is provided at the base of the housing, serves as a part of a frame constituting the base of the housing, and extends in a predetermined direction. A longitudinal end position of the frame member is disposed in an outer region located beyond an outer lateral edge position of the caster.

Abstract: An EGR device includes an EGR flow path, an EGR valve, a stepping motor, a motor driver, a return spring, a speed detector, and an opening degree estimator. The EGR flow path conveys exhaust gas from an exhaust flow path of an engine to an intake flow path. The EGR valve is disposed on the EGR flow path. The stepping motor drives the EGR valve to open to close. The motor driver supplies driving power to the stepping motor. The return spring urges the EGR valve in a valve closing direction. The speed detector detects an output shaft rotation speed of the engine. The opening degree estimator estimates an opening degree of the EGR valve. The motor driver changes a drive frequency of the stepping motor according to variations of the output shaft rotation speed detected by the speed detector and the opening degree estimated by the opening degree estimator.

Abstract: An EGR device includes an EGR flow path, an EGR valve, a stepping motor, a motor driver, a return spring, a speed detector, and an opening degree estimator. The EGR flow path conveys exhaust gas from an exhaust flow path of an engine to an intake flow path. The EGR valve is disposed on the EGR flow path. The stepping motor drives the EGR valve to open to close. The motor driver supplies driving power to the stepping motor. The return spring urges the EGR valve in a valve closing direction. The speed detector detects an output shaft rotation speed of the engine. The opening degree estimator estimates an opening degree of the EGR valve. The motor driver changes a drive frequency of the stepping motor according to variations of the output shaft rotation speed detected by the speed detector and the opening degree estimated by the opening degree estimator.

Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.

Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.

Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.

Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.